NCT05096715View on ClinicalTrials.gov

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 23, 2022

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2026

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Atezolizumab

Intravenous Infusion

DRUG

Bevacizumab

Intravenous Infusion

RADIATION

Stereotactic body radiation therapy (SBRT)

External Beam Radiation

Trial Locations (3)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

02215

NOT_YET_RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT05096715 - Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | Biotech Hunter | Biotech Hunter